Table 4.
Correlation analysis between solute carrier family 2 member 1 and solute carrier family 2 and genes markers of immune cells in gene expression profiling interactive analysis
| Description | Gene markers |
Solute carrier family 2 member 1
|
Solute carrier family 2 member 2
|
||
|
cor
|
P
value
|
cor
|
P
value
|
||
| CD8+ T cell | |||||
| CD8A | 0.24 | 3.10E-06 | -0.084 | 1.10E-01 | |
| CD8B | 0.26 | 3.20E-07 | -0.13 | 1.40E-02 | |
| T cell (general) | |||||
| CD3D | 0.18 | 5.10E-04 | -0.23 | 1.10E-05 | |
| CD3E | 0.15 | 4.00E-03 | -0.11 | 3.90E-02 | |
| CD2 | 0.17 | 1.50E-03 | -0.12 | 2.60E-02 | |
| B cell | |||||
| CD19 | 0.22 | 1.60E-05 | -0.073 | 1.60E-01 | |
| CD79A | 0.036 | 4.90E-01 | -0.59 | 2.60E-01 | |
| Monocyte | |||||
| CD86 | 0.39 | 1.50E-14 | -0.16 | 1.70E-03 | |
| CD115 (CSF1R) | 0.36 | 1.40E-12 | -0.14 | 5.40E-03 | |
| Tumor-associated macrophage | |||||
| CCL2 | 0.16 | 2.30E-03 | -0.13 | 1.50E-02 | |
| CD68 | 0.27 | 9.20E-08 | -0.14 | 6.50E-03 | |
| IL10 | 0.32 | 2.50E-10 | -0.095 | 6.70E-02 | |
| M1 macrophage | |||||
| INOS (NOS2) | -0.031 | 5.50E-01 | 0.2 | 1.20E-04 | |
| IRF5 | 0.14 | 7.40E-03 | 0.044 | 4.00E-01 | |
| COX2 (PTGS2) | 0.16 | 1.50E-03 | -0.028 | 5.90E-01 | |
| M2 macrophage | |||||
| CD163 | 0.31 | 7.00E-10 | -0.13 | 1.40E-02 | |
| VSIG4 | 0.36 | 1.10E-12 | -0.12 | 1.80E-02 | |
| MS4A4A | 0.29 | 1.50E-08 | -0.11 | 2.80E-02 | |
| CD66b (CEACAM8) | 0.074 | 1.60E-01 | -0.018 | 7.30E-01 | |
| Neutrophil | |||||
| CD11b (ITGAM) | 0.28 | 5.80E-08 | -0.074 | 1.60E-01 | |
| CCR7 | 0.039 | 4.60E-01 | -0.028 | 5.90E-01 | |
| Natural killer cell | |||||
| KIR2DL1 | 0.087 | 9.40E-02 | -0.059 | 2.60E-01 | |
| KIR2DL3 | 0.13 | 1.40E-02 | -0.05 | 3.40E-01 | |
| KIR2DL4 | 0.18 | 7.10E-04 | -0.12 | 2.00E-02 | |
| KIR3DL1 | 0.086 | 9.70E-02 | -0.058 | 2.70E-01 | |
| KIR3DL2 | 0.069 | 1.90E-01 | -0.0081 | 8.80E-01 | |
| KIR3DL3 | 0.08 | 1.30E-01 | -0.068 | 1.90E-01 | |
| KIR2DS4 | 0.044 | 4.00E-01 | 0.02 | 7.10E-01 | |
| Dendritic cell | |||||
| HLA-DPB1 | 0.25 | 1.40E-06 | -0.16 | 2.20E-03 | |
| HLA-DQB1 | 0.14 | 8.10E-03 | -0.19 | 2.60E-04 | |
| HLA-DRA | 0.26 | 6.00E-07 | -0.15 | 5.00E-03 | |
| HLA-DPA1 | 0.2 | 8.00E-05 | -0.12 | 2.30E-02 | |
| BDCA-1 (CD1C) | 0.12 | 2.40E-02 | -0.044 | 4.00E-01 | |
| BDCA-4 (NRP1) | 0.23 | 6.80E-06 | -0.037 | 4.80E-01 | |
| CD11c (ITGAX) | 0.24 | 2.00E-06 | -0.13 | 1.40E-02 | |
| Th1 | |||||
| T-bet (TBX21) | 0.088 | 9.00E-02 | -0.058 | 2.70E-01 | |
| STAT4 | 0.0027 | 9.60E-01 | -0.041 | 4.40E-01 | |
| STAT1 | 0.13 | 1.10E-02 | 0.017 | 7.50E-01 | |
| IFN-γ (IFNG) | 0.19 | 3.30E-04 | -0.1 | 4.70E-02 | |
| TNF-α (TNF) | 0.12 | 2.00E-02 | -0.1 | 5.40E-02 | |
| Th2 | |||||
| GATA3 | 0.31 | 2.10E-09 | -0.13 | 1.20E-02 | |
| STAT6 | 0.15 | 4.80E-03 | 0.19 | 2.40E-04 | |
| STAT5A | 0.2 | 8.20E-05 | -0.07 | 1.80E-01 | |
| IL13 | -0.025 | 6.30E-01 | -0.01 | 8.40E-01 | |
| Tfh | |||||
| BCL6 | 0.1 | 4.70E-02 | 0.24 | 2.70E-06 | |
| IL21 | 0.072 | 1.70E-01 | -0.044 | 3.90E-01 | |
| Th17 | |||||
| IL17A | -0.022 | 6.70E-01 | 0.071 | 1.80E-01 | |
| T cell regulatory | |||||
| FOXP3 | -0.036 | 4.90E-01 | 0.17 | 1.40E-03 | |
| CCR8 | 0.16 | 1.90E-03 | -0.082 | 1.20E-01 | |
| STAT5B | 0.073 | 1.60E-01 | 0.43 | 0.00E+00 | |
| TGFβ (TGFB1) | 0.24 | 2.10E-06 | -0.25 | 1.40E-06 | |
| T cell exhaustion | |||||
| PD-1 (PDCD1) | 0.08 | 1.20E-01 | -0.12 | 2.00E-02 | |
| CTLA4 | 0.17 | 1.10E-03 | -0.18 | 7.20E-04 | |
| LAG3 | 0.23 | 7.60E-06 | -0.19 | 3.30E-04 | |
| TIM-3 (HAVCR2) | 0.22 | 1.30E-05 | -0.17 | 1.30E-03 | |
| GZMB | 0.17 | 8.10E-04 | -0.16 | 2.20E-03 | |
cor: Correlation coefficient; L10: Interleukin 10; INOS: Nitric oxide synthase 2; IRF5: Interferon regulatory factor 5; COX2: Cytochrome c oxidase subunit II; VSIG4: V-set and immunoglobulin domain containing 4; MS4A4A: Membrane spanning 4-domains A4A; CCR7: C-C motif chemokine receptor 7; KIR2DL1: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1; KIR2DL3: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3; KIR2DL4: Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4; KIR3DL1: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1; KIR3DL2: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2; KIR3DL3: Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3; KIR2DS4: Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4; HLA-DPB1: Major histocompatibility complex, class II, DP beta 1; HLA-DQB1: Major histocompatibility complex, class II, DQ beta 1; HLA-DRA: Major histocompatibility complex, class II, DR alpha; HLA-DPA1: Major histocompatibility complex, class II, DP alpha 1; BDCA-4: Neuropilin 1; T-bet: T-box transcription factor 21; STAT4: Signal transducer and activator of transcription 4; STAT1: Signal transducer and activator of transcription 1; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor; GATA3: GATA Binding protein 3; STAT6: Signal transducer and activator of transcription 6; STAT5A: Signal transducer and activator of transcription 5A; IL13: Interleukin 13; BCL6: BCL6 transcription repressor; IL21: Interleukin 21; IL17A: Interleukin 17A; FOXP3: Forkhead box P3; CCR8: C-C motif chemokine receptor 8; STAT5B: Signal transducer and activator of transcription 5B; TGFβ: Transforming growth factor-beta; PD-1: Programmed cell death 1; CTLA4: Cytotoxic T-lymphocyte associated protein 4; LAG3: Lymphocyte activating 3; TIM-3: Hepatitis A virus cellular receptor 2; GZMB: Granzyme B; Th: T helper; Tfh: Follicular helper T.